Robert Ainscow Sells 8,438 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Robert Ainscow sold 8,438 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $6.20, for a total transaction of $52,315.60. Following the completion of the transaction, the chief executive officer directly owned 1,546,255 shares of the company’s stock, valued at approximately $9,586,781. This trade represents a 0.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Robert Ainscow also recently made the following trade(s):

• On Tuesday, November 25th, Robert Ainscow sold 25,000 shares of ASP Isotopes stock. The stock was sold at an average price of $5.77, for a total transaction of $144,250.00.
• On Monday, November 17th, Robert Ainscow sold 67,500 shares of ASP Isotopes stock. The stock was sold at an average price of $7.51, for a total transaction of $506,925.00.
• On Tuesday, October 14th, Robert Ainscow sold 22,500 shares of ASP Isotopes stock. The shares were sold at an average price of $13.60, for a total value of $306,000.00.

ASP Isotopes Price Performance

NASDAQ:ASPI opened at $5.94 on Friday. ASP Isotopes Inc. has a 52-week low of $3.65 and a 52-week high of $14.49. The company has a market cap of $658.39 million, a P/E ratio of -4.57 and a beta of 3.41. The company has a debt-to-equity ratio of 1.04, a quick ratio of 6.10 and a current ratio of 6.14. The stock’s 50-day simple moving average is $8.37 and its 200 day simple moving average is $8.69.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings results on Wednesday, November 19th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $2.25 million. ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. As a group, sell-side analysts forecast that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ASPI has been the topic of a number of recent analyst reports. Loop Capital set a $15.00 target price on shares of ASP Isotopes in a report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research report on Monday. Cantor Fitzgerald started coverage on shares of ASP Isotopes in a report on Thursday, December 4th. They issued an “overweight” rating and a $13.00 target price on the stock. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a research note on Monday, November 24th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $13.00.

Hedge Funds Weigh In On ASP Isotopes

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASPI. Quantbot Technologies LP bought a new position in shares of ASP Isotopes in the third quarter valued at about $34,000. Ameritas Investment Partners Inc. grew its stake in ASP Isotopes by 41.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock valued at $40,000 after buying an additional 1,600 shares during the last quarter. BNP Paribas Financial Markets grew its stake in ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares during the last quarter. Close Asset Management Ltd bought a new position in ASP Isotopes in the 3rd quarter valued at about $72,000. Finally, Tower Research Capital LLC TRC lifted its position in ASP Isotopes by 96.7% during the second quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock worth $80,000 after acquiring an additional 5,353 shares during the last quarter. 16.80% of the stock is owned by institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.